Gene | OATP4A1 (SLCO4A1) | OATP2A1 (SLCO2A1) | OATP2B1 (SLCO2B1) | OATP3A1 (SLCO3A1) | OCTN1 (SLC22A4) | OCTN2 (SLC22A5) | OCTN3 (SLC22A3) |
Protein | Solute carrier organic anion transporter family member 4A1 | Solute carrier organic anion transporter family member 2A1 | Solute carrier organic anion transporter family member 2B1 | Solute carrier organic anion transporter family member 3A1 | Solute carrier family 22 member4 | Solute carrier family 22 member5 | Solute carrier family 22 member3 |
Localization | N/A | N/A | mRNA in vascular endothelium, protein in human atria and ventricles | Expressed in ventricular cardiomyocytes | Human atrial and ventricular cardiomyocytes | Human atrial and ventricular cardiomyocytes | Localized in endothelial cells, partially colocalized with gap junction protein Cx43 |
Expression during postnatal development | N/A | N/A | N/A | N/A | N/A | Postnatal increase of OCTN2 | N/A |
Comments | Narrow substrate specificity | Mediates uptake and clearance of prostaglandins. Inhibited by multiple FDA-approved drugs. | Decreased expression after atorvastatin treatment | Increased uptake of simvastatin by OATP3A1 when combined with other OATP substrates | Transports drugs including quinidine, pyrilamine, verapamil, ipratropium, mitoxantrone, doxorubicin | l-carnitine transporter. Cephaloridine and cefepime produced competitive inhibition of l-carnitine transport. | Involved in cardiac monoamine uptake. |
References | Tamai et al., 2000; Fujiwara et al., 2001 | Lu et al., 1996; Kamo et al., 2017 | Grube et al., 2006; Roth et al., 2012 | Huber et al., 2007; Atilano-Roque and Joy, 2017 | Yabuuchi et al., 1999; Okabe et al., 2008; Nakamura et al., 2010 | Ganapathy et al., 2000; Srinivas et al., 2007 | Zwart et al., 2001 |